Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 5
2020 15
2021 31
2022 30
2023 31
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS).
Bilgin E, Demirci Yıldırım T, Özdemir Ulusoy B, Öğüt TS, Karabacak M, Sadioğlu Çağdaş Ö, Yıldırım R, Güven DC, Akleylek C, Ediboğlu E, Kutu ME, Özgür D, Kardaş RC, Bölek EÇ, Sandal Uzun G, Özsoy Z, Sarıyıldız E, Ayan G, Armağan B, Erden A, Kılıç L, Erbasan F, Alibaz-Öner F, Aşıcıoğlu E, Yazıcı A, Bilge NŞ, Küçük H, Çelik S, Bes C, Akar S, Yılmaz N, Kaşifoglu T, Cefle A, Direskeneli H, Yazısız V, Dizdar Ö, Omma A, Önen F, Karadağ Ö. Bilgin E, et al. Among authors: guven dc. Intern Emerg Med. 2024 Mar 29. doi: 10.1007/s11739-024-03577-9. Online ahead of print. Intern Emerg Med. 2024. PMID: 38553624
Sirolimus experience in adult patients with vascular malformations.
Akyildiz A, Ismayilov R, Guven DC, Yildirim HC, Tatar OD, Kus F, Chalabiyev E, Turker FA, Dizdar O, Yalcin S, Gullu HI. Akyildiz A, et al. Among authors: guven dc. Vascular. 2024 Mar 24:17085381241241853. doi: 10.1177/17085381241241853. Online ahead of print. Vascular. 2024. PMID: 38523367
Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab.
Yildirim HC, Anik H, Ozdemir DA, Ismayilov R, Akyildiz A, Cayiroz K, Ceyhan F, Kavruk O, Guven DC, Ates O, Usubutun A, Arik Z. Yildirim HC, et al. Among authors: guven dc. Biomol Biomed. 2024 Mar 5. doi: 10.17305/bb.2024.10255. Online ahead of print. Biomol Biomed. 2024. PMID: 38447002 Free article.
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
Karacin C, Sunar V, Urakci Z, Yilmaz A, Ayhan M, Ersoy M, Guven DC, Erturk I, Durmus Y, Karacin P, Boran N, Ustun YE, Meydan M, Dogan M, Oksuzoğlu B, Ates O, Karaca M, Uncu D, Ergun Y, Arik Z. Karacin C, et al. Among authors: guven dc. Future Oncol. 2024 Feb;20(4):207-214. doi: 10.2217/fon-2023-0763. Epub 2024 Feb 8. Future Oncol. 2024. PMID: 38328890
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ, Kutlu Y, Mutlu E, Aykan MB, Korkmaz M, Yalçın S, Şakalar T, Celayir ÖM, Kayıkçıoğlu E, Aslan F, Hafızoğlu E, Altıntaş YE, Keskinkılıç M, Chalabiyev E, Çelebi A, Dursun B, Kapar C, Özen M, Acar Ö, Dülgar Ö, Kut E, Biter S, Kus F, Almuradova E, Erdoğan AP, Saray S, Güven DC, Şimşek ET, Üskent N, Kemal Y, Çakar B, Açıkgöz Ö, Kılıçkap S, Aksoy S. Yıldırım HÇ, et al. Among authors: guven dc. Int J Clin Oncol. 2024 Mar;29(3):258-265. doi: 10.1007/s10147-023-02460-5. Epub 2024 Feb 4. Int J Clin Oncol. 2024. PMID: 38310597
110 results